Role of DEB-TACE Versus c-TACE in Treatment of HCC
Status:
Not yet recruiting
Trial end date:
2023-01-30
Target enrollment:
Participant gender:
Summary
Hepatocellular carcinoma (HCC) is listed as the sixth most common cancer worldwide and the
third most frequent cause of cancer-related mortality. The majority of HCC cases occurs stem
from chronic liver disease and cirrhosis.
Hepatocellular carcinoma accounts for approximately 70% to 90% of all primary liver cancers.
Trans-arterial Chemoembolization is the most widely utilized and is considered the first-line
treatment recommended for patients staged as intermediate HCC (Barcelona Clinic Liver Cancer
stage B). If applied correctly, TACE can produce survival benefits without adversely
affecting hepatic functional reserve.
Two TACE techniques have been used since 2004, conventional TACE (c-TACE) and TACE with
drug-eluting beads (DEB-TACE). Conventional TACE was evidenced first to treat intermediate
stage HCC patients.